Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes using fluridil (eucapil), minoxidil, and finasteride. One person takes 1 vial of fluridil daily and 1mg of finasteride every other day for effective treatment with minimal side effects.

The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

A 37-year-old man treated his hair loss with 0.5mg finasteride every other day and 5% minoxidil twice daily for 5 months, reducing finasteride from 1mg due to side effects. His hair improved significantly, with positive changes visible from all angles, and he experienced no more side effects after the dosage adjustment.

The user has been using 0.5mg finasteride every other day and applying minoxidil twice daily for three months but hasn't noticed any hair growth or increased thickness yet. They are questioning if they should expect progress at this stage.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

The user has been using Essengen 6+ (a mix of low-dose topical finasteride and minoxidil) for three months, seeing positive results, especially on the crown area. They also use Nizoral for dandruff and dermaroll weekly.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

A 26-year-old male with grade 3 hair loss is using 2.5 mg oral minoxidil, 1 mg finasteride, 5% minoxidil, ketoconazole shampoo, and kLM d3. He plans to post progress pictures every 6 weeks and is seeking suggestions.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

User shared a 3-month update on using finasteride and vitamins (Zinc, D3, B12, Magnesium) for hair loss. Progress pictures show improvement, and other users commented on their experiences and asked about specific vitamins.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Eucapil's effectiveness is questioned due to unconvincing clinical trial and lack of FDA approval.

The conversation discusses the effectiveness of different doses of finasteride for hair loss, questioning the need for 1mg daily when 0.5mg every other day has a similar impact on scalp DHT. A humorous reply suggests exaggerated side effects.

A user shared their 2-year progress using finasteride every other day with no side effects. Others discussed their experiences, shedding cycles, and patience with the treatment.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

BackToTheFutehair's 3.5 month progress update on their hair loss treatment regimen of finasteride, minoxidil, and microneedling which has led to a significant improvement in thickness and life to the hair. Others have provided encouragement and advice for future treatments.

The conversation is about a user sharing their 3-month progress with finasteride, minoxidil, and weekly derma rolling for hair loss. Some suggest buzzing the hair off to better apply treatments and consider a hair transplant in the future.

The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

User on fin, minox, and ketoconazole seeks to add another topical anti-androgen. Hierarchy of effectiveness: 1. RU55841, 2. Fluridil - Eucapil, 3. CB-03-01 - Breezula, 4. Ketoconazole; alfatradiol suggested as addition.

The conversation discusses hair regrowth progress from Norwood scale 4 to 2.5 over a year using daily 8.5-9% RU58841, topical Dutasteride 0.1%, RU58841 5% 1.5 times a week, and daily caffeine redensyl scalp treatment.

The conversation is about a person showing significant hair regrowth after three months using finasteride and minoxidil. Some people congratulated the person, while others asked if they used derma rolling or oral minoxidil, to which they replied they used topical minoxidil.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.